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ABSTRACT
Objective: The EQ-5D is a standardized, nondisease-speciﬁc
instrument for evaluating patients’ preference-based valua-
tions of health-related quality of life (HRQoL). This study’s
purpose was to determine the psychometric properties of
EQ-5D in patients with irritable bowel syndrome (IBS).
Methods: Data from four European IBS studies were
assessed: UK (n = 161 and n = 297), Spain (n = 503), and
Germany (n = 100). The EQ-5D is a ﬁve-item health state
descriptive system used to develop health states (EQ-
5DINDEX) and a visual analog scale (VAS) (0–100 from
worst to best imaginable health state, EQ-5DVAS). Meas-
ures used with the EQ-5D included the SF-36, Irritable
Bowel Syndrome—Quality of Life (IBS-QOL), and both
subjective and clinical global assessments of IBS. Conver-
gent validity was assessed using SF-36 and IBS-QOL data,
discriminant validity using global ratings of IBS severity,
and responsiveness by subjective and physician assessment
of condition.
Results: Moderate-to-high associations (r ≥ 0.33) were seen
between the EQ-5DVAS and the SF-36 and IBS-QOL subscales.
Mean response scores to EQ-5DINDEX dimensions and the EQ-
5DVAS score were signiﬁcantly better for control patients than
for patients with IBS (all P < 0.01). The EQ-5DVAS was able to
discriminate between levels of pain severity (quartiles,
P < 0.001; mild/moderate/severe, P < 0.05) and general
health severity (mild/moderate/severe, P < 0.001). The EQ-
5DVAS and the EQ-5DINDEX were responsive in patients using
both a self-perceived (Subject’s Global Assessment) and
physician-rated (Clinic Global Assessment) improvement.
Conclusions: The EQ-5D performs well in comparison to
general and disease-speciﬁc outcomes. It is a valid and
responsive measure that can be used to generate preference-
based valuations of HRQoL in patients with IBS and useful
for comparisons in clinical and cost-effectiveness studies.
Keywords: EQ-5D, irritable bowel syndrome, quality of life,
reliability, validity.
Introduction
Irritable bowel syndrome (IBS) is a chronic gastroin-
testinal (GI) dysmotility disorder characterized by
abdominal pain/discomfort, bloating and altered
bowel habit (constipation, diarrhea or alternating peri-
ods of both) [1–3]. IBS has a broad spectrum of symp-
tom severity, ranging from mild to severe and
intractable. IBS is a common condition with an esti-
mated symptom prevalence of 10% to 15% in Western
countries [1–4].
Patients with IBS often experience symptoms for
many years, with an average duration of 10 years or
more [5]. IBS causes signiﬁcant impairment to the
quality of life (QoL) for those patients having this con-
dition [6,7]. Patients with IBS experience physical role
limitations, greater pain and a lower perception of
their general health than those not having IBS. Epide-
miological studies show that IBS accounts for 50% of
visits to gastroenterologists in the United States and
41% of visits in the UK [8,9]. Nevertheless, only 30%
of patients with IBS in North America and Europe seek
medical treatment [8–13].
Most people can control their symptoms with diet,
stress management, and medications prescribed by
their physician. Nevertheless, traditional pharmaco-
therapies may not provide adequate relief of symptoms
[14] because these treatments target only one of the
multiple symptoms of IBS and may aggravate the oth-
ers [15,16]. For some people, IBS has a major impact
on QoL, affecting their work, social life and ability to
travel even short distances.
The assessment of health-related quality of life
(HRQoL) using patient-reported outcome (PRO)
measures has evolved greatly over the last decade. One
measure, the EuroQoL (EQ-5D), was developed
jointly by a group of European-based researchers with
the intent of constructing a simple, self-administered
instrument that provided a composite index score rep-
resenting the preference for a given health state [17].
The EuroQoL group designed the new instrument to
be quick and easy to use, standardized and to be used
alongside other measures of health status. This instru-
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ment provides both a health proﬁle and index for indi-
viduals or groups that allow clinical and economic
evaluation of medical interventions [18].
Cardiovascular and oncology are two areas where
the EQ-5D has been used quite often, but new studies
in musculoskeletal, respiratory, and GI diseases in-
cluded the EQ-5D as generic questionnaire [19]. Fur-
thermore, the EQ-5D is one of a handful of measures
recommended for use in cost-effectiveness analyses by
the Washington panel on cost-effectiveness in health
and medicine [20].
Although one published study has evaluated IBS
populations using the EQ-5D [21], it did not speciﬁ-
cally address whether the EQ-5D is an appropriate and
meaningful tool to use in patients with IBS. Using data
from four separate studies of IBS (two in the UK, one
in Spain, and one in Germany), psychometric proper-
ties were assessed to determine the validity (focusing
on convergent and discriminant validity) and respon-
siveness of the EQ-5D in patients with IBS.
Methods
Data Sources
UK1 (n = 161) [21]. A study to identify the impact
of IBS on HRQoL, time off work, and the utilization
and cost of health services took place from February to
November 1998. A sample of patients with IBS diag-
nosed by their general practitioners (GPs) was
recruited from six practices in the Trent Region of the
UK. The GP practices were chosen to be representative
geographically and on the basis of deprivation level
and social class. The GPs selected patients from their
practice lists based on those prescribed antispasmodics
or bowel regulators and/or diagnosed with IBS. The
project researcher applied the Rome I criteria [22] to
diagnose patients with IBS and only those meeting the
criteria were included in the study in the IBS group.
UK2 (n = 297) [23]. A follow-up study to the UK1
was conducted, from May to September 2001, to fur-
ther assess the quality of life (QoL) and resource use by
patient-perceived IBS severity. The same enrollment,
inclusion, and exclusion criteria were used. IBS
patients were identiﬁed from GP records from 13 prac-
tices in the Shefﬁeld area of the UK. In addition to the
IBS sample, using the same methodology, 326 control
subjects were recruited, case matched, by their GPs, on
age, sex, and social characteristics. The IBS sample
consisted of male or female patients aged 20 to
65 years who were currently on antispasmodics/bowel
regulators, and/or had been diagnosed with IBS.
Spain  (n = 503)  [24]. This nationwide, multicenter
observational, prospective, cohort study, initiated in
October 2000, compared the impact of IBS on patients
with the three IBS subtypes: constipation, diarrhea or
alternating between constipation and diarrhea. The
study assessed GI symptoms, QoL, psychological well-
being, use of resources and environmental stress.
Eighty-ﬁve gastroenterologists and 25 primary care
doctors were involved. Subjects meeting Rome II cri-
teria [25] were recruited from primary health-care
centers, external hospital clinics, specialized medical
centers, and other outpatient care sites.
Germany  (n = 100)  [26]. This observational study
aimed at assessing the impact of IBS on QoL and the
utility beneﬁts of tegaserod began in 1999. This study
used the EQ-5D and the disease-speciﬁc QoL question-
naire (IBS-QOL) to design a decision model to link the
QoL beneﬁts of tegaserod based on IBS pain severity.
Patients with a diagnosis of IBS, and who had been
treated for IBS for at least 12 months prior to enroll-
ment, were interviewed by a random selection of pri-
vate practice physicians.
QoL Assessment (Table 1)
EQ-5D. The EQ-5D consists of two parts: the health
states descriptive system and the visual analog rating
scale (VAS). The descriptive system records the level of
self-reported problems on each of the ﬁve dimensions
of the classiﬁcation (mobility, self-care, usual activities,
pain/discomfort, anxiety/depression). For each dimen-
sion the respondent is asked to choose between three
options: no problem, some/moderate problems, or
extreme problems/unable. Health states deﬁned by the
ﬁve-dimensional descriptive system can be converted
into a weighted health state index by applying scores
from value sets elicited from general population sam-
ples [27]. Respondents then describe their own health
status using a VAS. A 20-cm vertical VAS has become
the standard means of obtaining valuations for health
states. The endpoints of the VAS are labeled “best
imaginable health state” and “worst imaginable health
state” anchored at 100 and 0, respectively. Respond-
ents are asked to indicate how they rate their own
health state by drawing a line from an anchor box to
that point on the VAS that best represents their own
health on that day [18]. UK English, Spanish, and Ger-
man versions have been adapted culturally and trans-
lated [28].
SF-36. The Medical Outcomes Trust Short Form 36-
Item Health Survey (SF-36) is a generic measure of
functional status and well-being [29]. It contains 36
questions that measure health across eight dimen-
sions—physical functioning (PF), role limitations
because of physical health (RP), role limitation because
of emotional health (RE), social functioning (SF), bod-
ily pain (BP), mental health (MH), vitality or energy
(VT), and general health perception (GH). Responses
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to each question within a dimension are combined to
generate a score from 0 to 100, where 100 indicates
“good health” and 0 indicates “poor health.” The SF-
36 survey was included only in the UK studies pre-
sented in this article.
IBS-QOL. The Irritable Bowel Syndrome—Quality of
Life questionnaire (IBS-QOL) is a 34-item condition-
speciﬁc instrument allowing the evaluation of QoL of
patients with IBS by means of eight domains (dyspho-
ria, interference with activity, body image, health
worry, food avoidance, social reactions, sexual, and
relationships). This questionnaire has proved to be
valid and reliable for IBS patients [30,31] and has been
used in a wide range of clinical trials.
Clinical Variables
To aid the evaluation of validity of the EQ-5D in IBS
patients, both subjective and clinical (physician) global
assessments  of  pain  were  used.  In  the  UK  studies,  a
0- to 100-point VAS item was given to the patient to
rate their assessment of IBS-related pain severity on
abdominal pain and discomfort (VAS-ADP). In the
Spanish study, a similar VAS item was given to both
subjects and physicians to rate IBS severity. In the
study from Germany, the severity was deﬁned by sub-
ject’s rating of severity as mild, moderate or severe.
Data Analyses
Participants who completed the QoL assessments at
baseline in all studies were included in the analysis.
EQ-5D scores from each study were described by their
mean, standard deviation, median, interquartile range,
and the percent of scores at the ﬂoor and ceiling of the
distribution. All analyses were conducted using SPSS®
for Windows, Release 11.5 [32].
The validity of the EQ-5D was tested by means of
comparisons with validated instruments used to meas-
ure various characteristics of health status. Construct
validity of the ﬁve individual EQ-5D items and EQ-
5DVAS was tested using Spearman correlations with the
SF-36 domains and the IBS-QOL subscales and total
score. Using a correlation between 0.3 and 0.5 as the
deﬁnition for moderate correlation and correlations of
at least 0.5 for strong correlations [33], the following
relationships were hypothesized:
1. Correlations between EQ-5D and the SF-36
would be stronger than those between EQ-5D and
IBS-QOL because the EQ-5D and the SF-36 are
both generic measures of health status and the
IBS-QOL is an IBS-speciﬁc measure.
2. EQ-5D mobility would be strongly associated
with the SF-36 physical function domain and
moderately correlated with the SF-36 social func-
tioning domain.
3. EQ-5D pain/discomfort would be strongly corre-
lated with SF-36 bodily pain domain and moder-
ately correlated with the SF-36 physical
functioning domain.
4. EQ-5D anxiety/depression item would be strongly
associated with the SF-36 mental health domain
and moderately correlated with the SF-36 vitality
domain.
5. EQ-5DVAS would be moderately to-strongly corre-
lated with the SF-36 general health domain.
6. EQ-5D pain/discomfort would have stronger
associations with the IBS-QOL domains and total
score than the other EQ-5D items.
Known-groups construct (discriminant) validity of
the EQ-5DVAS (all studies) and the EQ-5DINDEX (in UK
studies only) was examined by testing the hypothesis
that as IBS severity increases (or worsens), the EQ-5D
scores decrease (health status also becomes worse).
Results from the subject’s global assessment and VAS-
ADP item (available in the UK2 study) were divided
into tertiles and used to graph the mean EQ-5DVAS
scores. Results were investigated for the German study
by graphing the EQ-5DVAS mean scores against the sub-
ject’s response of mild, moderate, and severe IBS pain;
Table 1 Instruments used in the quality of life questionnaires
Instrument
Number of
questions Issues covered Measurement
SF-36 36 Eight dimensions: physical functioning, role 
limitations because of physical health, role 
limitation because of emotional health, social 
functioning, bodily pain, mental health, vitality or 
energy and general health perception
Responses to each question within a dimension are 
combined to generate a score from 0 to 100, where 
100 indicates good health and 0 indicates poor 
health
EQ-5D* 5 Mobility, self-care, usual activities, pain, and anxiety −0.6 to 1 scale that was multiplied by 100 for 
compatibility with the SF-36 and IBS-QOL: −60 to 
100. A value of 100 indicates good health, 0 death 
and negative values health states worse than death
IBS-QOL 34 Overall score, 8 subscale scores including: dyspho-
ria, interference with activity, body image, health 
worry, food avoidance, social reaction, sexual, 
and relationships
100 indicates highest possible QoL and 0 indicates 
worst possible HRQoL
*The EQ-5D includes the EQ-5D visual analog rating scale.
EQ-5D, EuroQOL instrument; HRQoL, health-related quality of life; IBS-QOL, Irritable Bowel Syndrome—Quality of Life questionnaire; QoL, quality of life; SF-36, Medical Out-
comes Study 36-item Short Form health survey.
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and for the Spanish study using the subject’s response
on a seven-point severity of IBS scale (very good to
very bad). No assessment of severity was available in
the UK1 study. Analysis of variance was used to eval-
uate differences between groups. Group differences
were identiﬁed using Scheffe post hoc procedures.
To assess responsiveness, data from Spain were used
because this study included a 1-year follow-up meas-
urement. Mean change scores (between baseline and 1
year) were calculated for both subjective and physician
global ratings of IBS severity. Based on these change
scores, subjects’ IBS was identiﬁed as having improved,
remained the same, or declined in severity. EQ-5DVAS
and EQ-5DINDEX scores were then compared across the
change in IBS severity. Responsiveness was reported in
terms of the effect size statistic (mean change score
divided by the standard deviation of baseline score)
[34]. This effect size identiﬁed the differences in EQ-
5D scores associated with the change in IBS severity
over time.
Results
The study samples included: UK1, 161 subjects; UK2,
297 subjects; Spain, 503 subjects; and Germany, 100
subjects. The majority of subjects were female in all
studies (Table 2) with a mean age of between 43 and
54 years. As seen in Figure 1, the mean scores for each
of the ﬁve EQ-5D dimensions were very similar across
the different studies. Median scores were 1.00 for
mobility, self-care, and usual activities, and 2.00 for
pain/discomfort and anxiety/depression in all studies.
On individual questions, fewer people reported prob-
lems with EQ-5D self-care (8.1% in UK1, 12.8% in
UK2, 5.2% in Spain, and 0% in Germany). The major-
ity of subjects reported experiencing pain/discomfort
(83.2% in UK1, 84.2% in UK2, 77.0 in Spain, and
93.0% in Germany). The mean EQ-5DVAS score ranged
from 55.3 in Germany to 62.4 in UK1 and the EQ-
5DINDEX scores ranged from 0.62 in UK2 to 0.70 in
Spain (Fig. 2). Figure 2 also includes mean EQ-5D
scores for the control group (n = 326) included in the
UK2 study. The scores (VAS = 81.0, INDEX = 0.84)
indicate that the EQ-5D is able to detect differences
between individuals with IBS and controls (P < 0.001).
The hypothesized relationships were conﬁrmed
between the EQ-5D and the SF-36 (Table 3) and IBS-
QOL domain scores (Table 4). The correlations
between the EQ-5D and SF-36 were generally stronger
than those found between the EQ-5D and IBS-QOL.
The EQ-5D mobility item correlated strongly with the
SF-36 physical function domain (−0.70 and −0.71).
The EQ-5D pain/discomfort item correlated strongly
with the SF-36 bodily pain domain (−0.63 and −0.66).
The EQ-5D anxiety/depression item was strongly cor-
related with the SF-36 mental health domain (−0.65
and −0.60). The EQ-5DVAS item was most strongly
associated  with  the  SF-36  general  health  domain
(−0.71 and −0.67). Correlations between the EQ-5D
items and the IBS-QOL total score were all moderate
(−0.30 to 0.51) in the UK2 study. In the Spanish study,
the EQ-5D usual activities, pain/discomfort and anxi-
ety/depression items had moderate correlations with
the IBS-QOL (−0.31 to 0.47), but the EQ-5D mobility
and  self-care  items  were  smaller,  but  still  signiﬁcant
(−0.12). Associations in UK1 and German studies were
similar (Table 4).
Figure 3 shows that the predicted relationship be-
tween the EQ-5DVAS score and the VAS-ADP (deﬁned
in quartiles) was conﬁrmed in the UK2 study. EQ-
5DVAS scores decreased as levels of subjective severity
increased (F = 22.1; P < 0.001). Similar results were
Table 2 Sample characteristics
Sample Description
Age (year)
(mean, SD)
Sex 
(% female)
UK1 (n = 161) To identify impact of IBS on HRQoL, work, and utilization 47.1 (11.9) 86.3
UK2 (n = 297) To compare HRQoL, utilization, and cost by self-perceived IBS severity 48.2 (11.6) 83.9
Spain (n = 503) Observational study to assess impact of IBS in Spain 42.7 (15.2) 75.9
Germany (n = 100) Observational study to assess impact of IBS in Germany 53.8 (15.6) 80.0
HRQoL, health-related quality of life; IBS, irritable bowel syndrome.
Figure 1 EQ-5D descriptive system mean
scores. Note: Higher scores indicate greater
negative impacts.
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Figure 3 EQ-5DVAS by subject’s global assessment (SGA) of pain severity
(VAS scale). Data source: UK2 (n = 297). CI, conﬁdence interval; VAS, vis-
ual analog rating scale.
1049598N =
SGA of pain severity (VAS—Tertiles)
T3 (58–100)T2 (35–57)T1 (0–34)
9
5
%
 C
I 
E
Q
-5
D
 o
ve
ra
ll 
ut
ili
ty
 (
V
A
S
)
80
70
60
50
40
F=27.3; P<0.001
observed in the German study where EQ-5DVAS scores
decreased as subject’s assessment of their IBS pain in-
creased (F = 4.4; P < 0.05) (Fig. 4) and in Spain where
EQ-5DVAS scores decreased as IBS severity increased
(F = 16.8; P < 0.001) (data not shown). The EQ-
5DINDEX discriminated between tertiles of subjective
pain severity, decreasing as levels of severity increased
(data from the UK2, F = 29.3; P < 0.001) (Fig. 5).
Figure 6 shows the responsiveness of the EQ-5DVAS
score for different levels of subjective and physician glo-
bal assessments of IBS severity from the data collected
in Spain. Subjects who reported a decline or worsening
in IBS severity also experienced a decline in EQ-5DVAS
scores. Subjects for whom IBS severity remained the
same experienced slight improvements in EQ-5DVAS
mean scores, whereas those who improved reported
large improvements in EQ-5DVAS scores. The clinician
rating of severity resulted in smaller amounts of patient-
reported levels of improvement and decline in EQ-
5DVAS scores. Effect size statistics were 0.64 for VAS-
Figure 2 EQ-5DVAS and EQ-5DINDEX scores by
study. Note: EQ-5DINDEX scores have been multi-
plied by 100 for comparison; Error bars represent
standard error of the mean. VAS, visual analog
rating scale.
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Table 3 Correlations between the EQ-5D and the SF-36
EQ-5D
SF-36 domains
Social
function Role—emotional
Mental
health Vitality
Physical
function Role—physical
Bodily
pain
General
health
UK1 (n = 161)
Mobility −0.479† −0.169 −0.117 −0.366† −0.704† −0.182 −0.501† −0.479†
Self-care −0.342† −0.220* −0.051 −0.300† −0.568† −0.097 −0.377† −0.314†
Usual activities −0.593† −0.240† −0.230† −0.491† −0.575† −0.402† −0.606† −0.588†
Pain/discomfort −0.434† −0.150 −0.207* −0.441† −0.436† −0.278† −0.626† −0.456†
Anxiety/depression −0.458† −0.452† −0.598† −0.389† −0.199* −0.155 −0.316† −0.364†
EQ-5DVAS 0.562† 0.135 0.352† 0.676† 0.550† 0.330† 0.534† 0.669†
UK2 (n = 297)
Mobility −0.559† −0.363† −0.276† −0.394† −0.711† −0.555† −0.618† −0.556†
Self-care −0.483† −0.334† −0.191† −0.347† −0.587† −0.368† −0.438† −0.473†
Usual activities −0.608† −0.461† −0.361† −0.448† −0.554† −0.683† −0.565† −0.567†
Pain/discomfort −0.509† −0.342† −0.307† −0.410† −0.536† −0.438† −0.662† −0.560†
Anxiety/depression −0.443† −0.487† −0.645† −0.433† −0.268† −0.296† −0.332† −0.358†
EQ-5DVAS 0.613† 0.485† 0.477† 0.536† 0.588† 0.565† 0.609† 0.710†
*Correlation is signiﬁcant at the 00.05 level (2-tailed).
†Correlation is signiﬁcant at the 00.01 level (2-tailed).
VAS, visual analog rating scale.
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ADP and 0.48 for the Clinician’s Global Assessment
(CGA). Mean group comparisons showed each of these
differences to be signiﬁcant (P < 0.001). Similar trends
were seen using the EQ-5DINDEX score with effect size of
0.33 and 0.29, respectively.
Discussion
Any PRO measure, such as the EQ-5D, should dem-
onstrate satisfactory properties before being used in
studies of speciﬁc populations, such as patients with
Table 4 Correlations between the EQ-5D and the IBS-QOL
IBS-QOL
Dysphoria
Interference 
with activity
Body 
image
Health 
worry
Food 
avoidance
Social 
reaction Sexual Relationship
Overall 
score
UK1 (n = 161)
Mobility −0.177* −0.291† −0.114 −0.209† −0.205* −0.174* −0.116 −0.210† −0.191*
Self-care −0.125 −0.175* −0.201* −0.120 −0.077 −0.118 −0.106 −0.239† −0.149
Usual activities −0.383† −0.460† −0.371† −0.379† −0.266† −0.401† −0.260† −0.323† −0.442†
Pain/discomfort −0.318† −0.388† −0.362† −0.395† −0.264† −0.336† −0.251† −0.260† −0.380†
Anxiety/depression −0.418† −0.342† −0.278† −0.352† −0.287† −0.358† −0.260† −0.357† −0.433†
EQ-5DVAS 0.391† 0.406† 0.325† 0.423† 0.263† 0.347† 0.305† 0.369† 0.470†
UK2 (n = 297)
Mobility −0.268† −0.301† −0.212† −0.195† −0.242† −0.270† −0.280† −0.230† −0.304†
Self-care −0.283† −0.325† −0.207† −0.221† −0.216† −0.234† −0.351† −0.251† −0.311†
Usual activities −0.311† −0.340† −0.246† −0.257† −0.214† −0.240† −0.325† −0.248† −0.335†
Pain/discomfort −0.444† −0.441† −0.395† −0.375† −0.329† −0.350† −0.384† −0.343† −0.484†
Anxiety/depression −0.367† −0.323† −0.308† −0.289† −0.206† −0.277† −0.207† −0.309† −0.363†
EQ-5DVAS 0.536† 0.532† 0.392† 0.425† 0.401† 0.420† 0.396† 0.433† 0.519†
Spain (n = 503)
Mobility −0.092* −0.133† −0.142† −0.113* −0.064 −0.031 −0.109* −0.067 −0.117†
Self-care −0.109* −0.104* −0.071 −0.114* −0.088* −0.084 −0.070 −0.052 −0.117†
Usual activities −0.385† −0.332† −0.266† −0.247† −0.255† −0.330† −0.385† −0.310† −0.408†
Pain/discomfort −0.287† −0.242† −0.257† −0.222† −0.261† −0.224† −0.250† −0.192† −0.314†
Anxiety/depression −0.358† −0.242† −0.268† −0.271† −0.335† −0.297† −0.283† −0.287† −0.380†
EQ-5DVAS 0.460† 0.304† 0.319† 0.318† 0.349† 0.360† 0.373† 0.364† 0.466†
Germany (n = 100)
Mobility −0.149 −0.154 0.075 −0.143 −0.152 −0.071 −0.136 −0.134 −0.150
Self-care 0‡ 0‡ 0‡ 0‡ 0‡ 0‡ 0‡ 0‡ 0‡
Usual activities −0.319† −0.269† −0.166 −0.201* −0.303† −0.124 −0.322† −0.149 −0.313†
Pain/discomfort −0.271† −0.074 −0.071 −0.181 −0.303† −0.301† −0.016 −0.047 −0.236*
Anxiety/depression −0.545† −0.386† −0.292† −0.426† −0.323† −0.364† −0.381† −0.457† −0.549†
EQ-5DVAS 0.396† 0.188 0.192 0.322† 0.279† 0.079 0.220* 0.145 0.322†
*Correlation is signiﬁcant at the 00.05 level (2-tailed).
†Correlation is signiﬁcant at the 00.01 level (2-tailed).
‡Cannot be computed because the “Self-Care” item is constant (all responses are “1”).
IBS-QOL, Irritable Bowel Syndrome—Quality of Life questionnaire; VAS, visual analog rating scale.
Figure 4 EQ-5DVAS by subject’s global assessment of pain (Categorical
scale). Data source: Germany (n = 100). CI, conﬁdence interval; VAS,
visual analog rating scale.
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Figure 5 EQ-5DINDEX by subject’s global assessment (SGA) of pain sever-
ity (VAS scale). Data source: UK2 (n = 297). CI, conﬁdence interval; VAS,
visual analog rating scale.
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IBS. Although there have been studies exploring the
health status of IBS patients [7,21,35], there is a lack of
information regarding the applicability and sensitivity
of these measures in determining the impact of IBS on
patients.
The present study has certain limitations that need
to be taken into account when considering the study
and its contributions. In this research, data were
obtained from several studies to provide evidence to
support the use of the EQ-5D in an IBS population.
Inclusion and diagnostic criteria varied across studies.
For example, in the UK1 study, patients meeting the
Rome I criteria for IBS were enrolled and the German
sample consisted of constipation-predominant or alter-
nating IBS patients). Another limitation in this analysis
includes the variation in measures used. Although the
data were collected from studies with divergent meth-
odologies in several European countries, the EQ-5D
scores remain similar with self-care having the least
impact and pain/discomfort having the greatest effect
on patients’ QoL.
From the studies in the UK, we observed that each
dimension of the EQ-5D was most highly associated
with the corresponding dimension measured concur-
rently by the SF-36. The strongest relationships were
seen between mobility (EQ-5D) and physical function-
ing (SF-36); the pain/discomfort dimension (EQ-5D)
and bodily pain (SF-36); and anxiety/depression (EQ-
5D) and mental health (SF-36).
The ability to convert EQ-5D scores to utility meas-
ures is advantageous because it provides a quantitative
expression of an individual’s preference for, or the
desirability of, a particular state of health under con-
ditions of uncertainty. These utility scores can then be
used as the quality weights when computing a quality-
adjusted life-year. This is a universal health outcome
measure that is applicable to all individuals and all dis-
eases, and enables comparisons across diseases and
across programs. This feature of the EQ-5D provides
greater support in cost-effectiveness studies where
more simple descriptive measures may not. It is noted
that the VAS scale should not be used to measure util-
ities directly, rather health state evaluations are more
relevant to obtain utility measures [36].
The EQ-5D performs well in comparison to general
and disease-speciﬁc outcomes and data presented in
this article demonstrate that it is a valid and responsive
PRO measure that can be used to generate preference-
based valuations of HRQoL in patients with IBS and
useful for comparisons in clinical and cost-effective-
ness studies.
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